ADVANCED OR METASTATIC NSCLC
Clinical trials for ADVANCED OR METASTATIC NSCLC explained in plain language.
Never miss a new study
Get alerted when new ADVANCED OR METASTATIC NSCLC trials appear
Sign up with your email to follow new studies for ADVANCED OR METASTATIC NSCLC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy shows promise for tough lung cancer
Disease control OngoingThis early-stage study tests a new drug combination (datopotamab deruxtecan plus pembrolizumab, with or without chemo) in 145 people with advanced or metastatic non-small cell lung cancer. The goal is to see if the treatment is safe and can shrink tumors or slow disease progressi…
Matched conditions: ADVANCED OR METASTATIC NSCLC
Phase: PHASE1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated May 20, 2026 11:56 UTC
-
New drug cocktail shows promise for tough lung cancer
Disease control OngoingThis study tests a new drug called datopotamab deruxtecan (Dato-DXd) combined with immunotherapy, with or without carboplatin, in people with advanced or metastatic non-small cell lung cancer (NSCLC). The goal is to see if the combination is safe and helps shrink tumors. About 15…
Matched conditions: ADVANCED OR METASTATIC NSCLC
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 19, 2026 12:00 UTC
-
New hope for tough lung cancers: drug combo shows promise
Disease control OngoingThis study tests a combination of two drugs, ceralasertib and durvalumab, in adults with advanced or metastatic non-small cell lung cancer that has worsened after standard treatments like immunotherapy and chemotherapy. The goal is to see if the combination can shrink tumors and …
Matched conditions: ADVANCED OR METASTATIC NSCLC
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 18, 2026 12:08 UTC